01/15/2025 11:30 |
StemRIM Announces the Extension of the Term for the Tripartite Joint Research Agreement Aimed at Elucidating Skin Anti-Aging Mechanisms |
12/23/2024 14:30 |
StemRIM Announces the First Administration of Phase 2 Clinical Trial for Redasemtide Targeting Ischemic Cardiomyopathy |
12/12/2024 12:30 |
[Delayed]Non-consolidated Financial Results for Three Months Ended October 31, 2024 |
12/12/2024 12:30 |
[Delayed]StemRIM Announces Selection for the AMED Project for Fundamental Technology Development of Regenerative Medicine and Gene Therapy |
12/11/2024 16:00 |
StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation |
12/09/2024 15:30 |
StemRIM Announces Patent Registration (Europe) for the Use of Redasemtide, as a Therapeutic Indication for Cardiomyopathy and Chronic Heart Failure |
12/05/2024 15:30 |
StemRIM Announces Patent Registration in Australia for Peptides Related to the HMGB1 Fragment Peptide, Redasemtide |
11/13/2024 15:30 |
StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock |
11/05/2024 15:30 |
StemRIM Announces Patent Registration in Japan for the HMGB1 Peptide, Redasemtide |
10/31/2024 15:00 |
Presentation Material for Business Plan and Growth Potential |
09/25/2024 16:00 |
Notice Regarding Appointment of Director Candidates |
09/25/2024 16:00 |
StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company's Executive Officers, Employees, and External Collaborators |
09/13/2024 15:30 |
Presentation Material, Financial Results for the Fiscal Year Ended July 31, 2024 |
09/11/2024 15:30 |
Notice Regarding Differences between Non consolidated Result s for Fiscal Year Ended July 31, 2024 and those for Previous Fiscal Year |
09/11/2024 15:30 |
Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2024 [Japanese GAAP] |
08/09/2024 16:20 |
StemRIM Announces Fixed Details of the Issuance of Stock Options to Temporary Employees and External Collaborator |
08/08/2024 15:45 |
StemRIM Announces Patent Registration in China for Peripheral Peptides of the HMGB1 Fragment Peptide, Redasemtide |
07/26/2024 16:30 |
StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees |
07/26/2024 16:30 |
StemRIM Announces Fixed Details of the Issuance of Stock Options to Directors |
07/25/2024 16:00 |
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Temporary Employees and External Collaborator |
07/25/2024 16:00 |
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees |
07/25/2024 16:00 |
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Directors |
07/08/2024 15:30 |
StemRIM Announces Patent Registration in Japan for Stem Cell Gene Therapy for Dystrophic Epidermolysis Bullosa |
06/17/2024 15:00 |
Patent Registration (Australia) for the Use of Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction |
06/12/2024 15:00 |
Non-consolidated Financial Results for the Nine Months Ended April 30, 2024 [Japanese GAAP] |
05/08/2024 15:00 |
StemRIM Announces Setting the Record Date for Extraordinary General Meeting of Shareholders , and Reduction of Capital Stock (Capital Decrease) |
03/21/2024 15:30 |
StemRIM Announces Symposium on "Regeneration-Inducing Medicine" at the 23rd Congress of the Japanese Society for Regenerative Medicine |
03/15/2024 16:00 |
Presentation Materials for the Six Months Ended January 31, 2024 |
03/13/2024 15:30 |
StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy |
03/13/2024 15:30 |
Non-consolidated Financial Results for the Six Months Ended January 31, 2024[Japanese GAAP] |
02/29/2024 16:00 |
StemRIM Announces Fixed Details of the Issuance of Stock Options to External Collaborators |
02/15/2024 15:00 |
StemRIM Announces Patent Registration (Japan) for the Use of Redasemtide, as a Therapeutic Indication of Therapeutic Medication for Cartilage Disorder |
02/14/2024 15:30 |
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to External Collaborators |